Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James L Weaver

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Clinical Pharmacology and Therapeutics|September 8, 2021
Expanding Approved Patient Populations for Rare Disease Treatment Using In Vitro DataJames L Weaver, Wendy Wu, Paula L Hyland, et al.
Current Drug Discovery Technologies|February 14, 2006
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modelingEdwin J Matthews, Naomi L Kruhlak, James L Weaver, et al.
Journal of Pharmaceutical and Biomedical Analysis|December 3, 2014
Development and validation of a liquid-chromatography tandem mass spectrometry method to determine in vitro and in vivo histamine releaseKrishna C Chimalakonda, Eric Pang, James L Weaver, et al.
Antibiotics (Basel, Switzerland)|December 23, 2022
Evaluation of a Sequential Antibiotic Treatment Regimen of Ampicillin, Ciprofloxacin and Fosfomycin against <i>Escherichia coli</i> CFT073 in the Hollow Fiber Infection Model Compared with Simultaneous Combination TreatmentAshok Krishna, Tesfalem Zere, Sabyasachy Mistry, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|May 30, 2003
Evaluation of the Tg.AC assay: specificity testing with three noncarcinogenic pharmaceuticals that induce selected stress gene promoters in vitro and the inhibitory effects of solvent componentsKarol L Thompson, Barry A Rosenzweig, James L Weaver, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|March 10, 2019
BLT-Immune Humanized Mice as a Model for Nivolumab-Induced Immune-Mediated Adverse Events: Comparison of the NOG and NOG-EXL StrainsJames L Weaver, Leah M Zadrozny, Kathleen Gabrielson, et al.
Physical Review Letters|March 21, 2008
Enhanced direct-drive implosions with thin high-Z ablation layersAndrew N Mostovych, Denis G Colombant, Max Karasik, et al.
Toxicologic Pathology|June 30, 2010
Early events in vascular injury in the rat induced by the phosphodiesterase IV inhibitor SCH 351591James L Weaver, Jun Zhang, Alan Knapton, et al.
International Journal of Antimicrobial Agents|December 16, 2019
Effect of drug combinations on the kinetics of antibiotic resistance emergence in Escherichia coli CFT073 using an in vitro hollow-fibre infection modelNarayana Garimella, Tesfalem Zere, Neil Hartman, et al.
Toxicology and Applied Pharmacology|March 28, 2019
Evaluation of a TGN1412 analogue using in vitro assays and two immune humanized mouse modelsHangyi Yan, Bhagyashree Bhagwat, David Sanden, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Clinical Pharmacology and Therapeutics|September 8, 2021
Expanding Approved Patient Populations for Rare Disease Treatment Using In Vitro DataJames L Weaver, Wendy Wu, Paula L Hyland, et al.
Current Drug Discovery Technologies|February 14, 2006
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modelingEdwin J Matthews, Naomi L Kruhlak, James L Weaver, et al.
Journal of Pharmaceutical and Biomedical Analysis|December 3, 2014
Development and validation of a liquid-chromatography tandem mass spectrometry method to determine in vitro and in vivo histamine releaseKrishna C Chimalakonda, Eric Pang, James L Weaver, et al.
Antibiotics (Basel, Switzerland)|December 23, 2022
Evaluation of a Sequential Antibiotic Treatment Regimen of Ampicillin, Ciprofloxacin and Fosfomycin against <i>Escherichia coli</i> CFT073 in the Hollow Fiber Infection Model Compared with Simultaneous Combination TreatmentAshok Krishna, Tesfalem Zere, Sabyasachy Mistry, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|May 30, 2003
Evaluation of the Tg.AC assay: specificity testing with three noncarcinogenic pharmaceuticals that induce selected stress gene promoters in vitro and the inhibitory effects of solvent componentsKarol L Thompson, Barry A Rosenzweig, James L Weaver, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|March 10, 2019
BLT-Immune Humanized Mice as a Model for Nivolumab-Induced Immune-Mediated Adverse Events: Comparison of the NOG and NOG-EXL StrainsJames L Weaver, Leah M Zadrozny, Kathleen Gabrielson, et al.
Physical Review Letters|March 21, 2008
Enhanced direct-drive implosions with thin high-Z ablation layersAndrew N Mostovych, Denis G Colombant, Max Karasik, et al.
Toxicologic Pathology|June 30, 2010
Early events in vascular injury in the rat induced by the phosphodiesterase IV inhibitor SCH 351591James L Weaver, Jun Zhang, Alan Knapton, et al.
International Journal of Antimicrobial Agents|December 16, 2019
Effect of drug combinations on the kinetics of antibiotic resistance emergence in Escherichia coli CFT073 using an in vitro hollow-fibre infection modelNarayana Garimella, Tesfalem Zere, Neil Hartman, et al.
Toxicology and Applied Pharmacology|March 28, 2019
Evaluation of a TGN1412 analogue using in vitro assays and two immune humanized mouse modelsHangyi Yan, Bhagyashree Bhagwat, David Sanden, et al.
Pageof 5